8/31/2020 8:30:08 AM
Eiger Announces Peginterferon Lambda - Lonafarnib Combination End Of Treatment Results From Phase 2 LIFT HDV Study
4/30/2020 8:10:49 AM
Eiger BioPharma Unveils First COVID-19 Patient Dosed With Peginterferon Lambda
3/23/2020 8:22:44 AM
Eiger BioPharma Completes Submission Of NDA To FDA For Lonafarnib For Progeria And Progeroid Laminopathies
3/13/2020 8:01:46 AM
Eiger BioPharma Q4 Net Loss $16.9 Mln Or $0.69/Shr Vs Loss $16.5 Mln Or $0.93/Shr Last Year
10/21/2019 9:03:44 AM
Eiger Announces Peginterferon Lambda Combination Therapy For Treatment Of Chronic Hepatitis Delta Virus Infection
8/20/2019 8:03:10 AM
Eiger Announces FDA Breakthrough Therapy Designation For Peginterferon Lambda For HDV Infection
6/18/2019 10:22:33 AM
Wedbush Reiterates Eiger BioPharmaceuticals Inc. (EIGR) At Outperform With $35 Price Target
5/9/2019 4:06:20 PM
Eiger BioPharma Q1 Loss/share $0.90 Vs. Loss $0.84 Year Ago
4/17/2019 11:22:40 PM
Eiger BioPharmaceuticals Prices Public Offering Of 4.50 Mln Shares At $11.00/shr
4/17/2019 4:02:43 PM
Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock
3/28/2019 7:21:51 AM
Wedbush Reiterates Eiger BioPharmaceuticals Inc. (EIGR) At Outperform With $43 Price Target
3/14/2019 4:12:53 PM
Eiger BioPharmaceuticals Q4 Loss/share $0.92 Vs. Loss $1.11 Year Ago
3/13/2019 8:04:52 AM
Eiger Reports Late-Breaker Oral Presentation Of Peginterferon Lambda Phase 2 LIMT Study At Int'l Liver Congress 2019
2/6/2019 8:09:18 AM
Eiger BioPharma Says Patent Protection For Lonafarnib Boosted With Ritonavir For HDV Infection In Europe And Japan
2/4/2019 8:14:31 AM
Eiger Says An Oral Presentation Granted For Results Of Phase 2 PREVENT Study At ENDO 2019
12/19/2018 8:09:02 AM
Eiger Says Breakthrough Therapy Designation Granted By FDA For Lonafarnib